John H Friedman Net Worth

The estimated Net Worth of John H Friedman is at least $11.1 Million dollars as of 7 November 2013. John Friedman owns over 90,130 units of Cardiovascular Systems stock worth over $3,322,240 and over the last 19 years John sold CSII stock worth over $7,776,275.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

John Friedman CSII stock SEC Form 4 insiders trading

John has made over 13 trades of the Cardiovascular Systems stock since 2011, according to the Form 4 filled with the SEC. Most recently John sold 90,130 units of CSII stock worth $2,677,762 on 7 November 2013.

The largest trade John's ever made was selling 90,130 units of Cardiovascular Systems stock on 7 November 2013 worth over $2,677,762. On average, John trades about 24,323 units every 31 days since 2006. As of 7 November 2013 John still owns at least 166,112 units of Cardiovascular Systems stock.

You can see the complete history of John Friedman stock trades at the bottom of the page.

What's John Friedman's mailing address?

John's mailing address filed with the SEC is C/O ACORDA THERAPEUTICS, INC, 15 SKYLINE DRIVE, HAWTHORNE, NY, 10532.

Insiders trading at Cardiovascular Systems

Over the last 16 years, insiders at Cardiovascular Systems have traded over $72,999,461 worth of Cardiovascular Systems stock and bought 949,532 units worth $8,687,068 . The most active insiders traders include Capital Management Lp Camber, Augustine Lawlor, and Capital Ltdmaverick Capital.... On average, Cardiovascular Systems executives and independent directors trade stock every 14 days with the average trade being worth of $338,920. The most recent stock trade was executed by Martha Goldberg Aronson on 15 August 2022, trading 2,411 units of CSII stock currently worth $48,220.

What does Cardiovascular Systems do?

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company's orbital atherectomy system treats calcified and fibrotic plaque in arterial vessels throughout the leg and heart and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives.

Complete history of John Friedman stock trades at Acorda Therapeutics Inc and Cardiovascular Systems

Cardiovascular Systems executives and stock owners

Cardiovascular Systems executives and other stock owners filed with the SEC include:

• Scott Ward,
  Chairman of the Board, President, Chief Executive Officer
• Rhonda Robb,
  Chief Operating Officer
• Scott Raymond Ward B.Sc., M.S., MS,
  Chairman, Pres & CEO
• Scott Raymond Ward M.S., MS, B.Sc.,
  Chairman, Pres & CEO
• Jeffrey Points,
  Chief Financial Officer
• Alexander Rosenstein,
  General Counsel and Corporate Secretary
• Ryan Egeland,
  Chief Medical Officer
• Rhonda J. Robb,
  Chief Operating Officer
• Sandra Sedo,
  Chief Compliance Officer
• Jeffrey S. Points,
  Chief Financial Officer
• Alexander Rosenstein,
  Gen. Counsel & Corp. Sec.
• Dr. Ryan D. Egeland M.D., Ph.D.,
  Chief Medical Officer
• Edward Brown,
  Independent Director
• Augustine Lawlor,
  Independent Director
• Martha Aronson,
  Independent Director
• Erik Paulsen,
  Independent Director
• William Cohn,
  Independent Director
• Stephen Stenbeck,
  Independent Director
• Stephen Rempe,
  Chief Human Resource Officer
• Kelvin Womack,
  Independent Director
• David Whitescarver,
  Vice President - Corporate Development and Intellectual Property
• John Hastings,
  Vice President - Manufacturing and Operations
• Stephen J. Rempe,
  Chief HR Officer
• David S. Whitescarver,
  VP of Corp. Devel. & Intellectual Property
• Sandra M. Sedo,
  Chief Compliance Officer
• John M. Hastings,
  Exec. VP of Operations & Technology
• John E. Nielsen,
  VP of Investor Relations & Corp. Communications
• Brent G Blackey,
  Director
• Leslie Trigg,
  Director
• Capital Management Lp Camber,
  10% owner
• Scott A Bartos,
  Director
• Laurence L Betterley,
  Chief Financial Officer
• Kevin J. Kenny,
  Chief Operating Officer
• Laura Gillund,
  Chief Talent Officer
• Sachin H. Jain,
  Director
• Capital Ltdmaverick Capital...,
  
• Gary M Petrucci,
  Director
• Paul A. Koehn,
  SVP Quality & Operations
• James E Flaherty,
  Chief Administrative Officer
• Glen D Nelson,
  Director
• Robert J Thatcher,
  Executive VP
• David Martin,
  President and CEO
• Geoffrey O Hartzler,
  Director
• Brian Doughty,
  VP of Marketing
• Paul A Tyska,
  VP of Business Dev
• Roger J Howe,
  Director
• Group I, Llc Donoghue Danie...,
  
• John H Friedman,
  Director
• Scott William Kraus,
  VP Sales
• Advisors, Inc Bonderman Dav...,
  
• Geoffrey M Duyk,